Irina Muni, MD
Internal Medicine · Bloomfield, CTNPI 1215958301
Payments from drug & device makers
Across 162 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$770
- AstraZeneca$219
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$216
- Boehringer Ingelheim$213
- Amgen$169
- Astellas Pharma US Inc$161
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,952100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $770 |
| AstraZeneca | 13 | $219 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $216 |
| Boehringer Ingelheim | 11 | $213 |
| Amgen | 8 | $169 |
| Astellas Pharma US Inc | 8 | $161 |
| GSK | 8 | $138 |
| Abbott | 6 | $135 |
| Sanofi-aventis U.S. LLC | 7 | $105 |
| Lilly USA, LLC | 7 | $100 |
| AbbVie(2 entities) | 5 | $88 |
| Actelion Pharmaceuticals US, Inc. | 3 | $82 |
| Scilex Pharmaceuticals Inc. | 4 | $73 |
| Avanir Pharmaceuticals, Inc. | 4 | $58 |
| Johnson & Johnson | 4 | $55 |
| Pfizer | 3 | $52 |
| Novartis | 2 | $28 |
| Biomerieux Inc | 1 | $28 |
| Exact Sciences | 1 | $27 |
| Genentech USA, Inc. | 2 | $27 |
| Dexcom, Inc. | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 1 | $23 |
| Seqirus USA Inc | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 2 | $23 |
| Eisai Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $19 |
| Medtronic | 1 | $19 |
| Merck | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $13 |
How this compares
$2,952 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 117 | $146,829 |
| JardianceEmpagliflozin | 90 | $115,014 |
| EliquisApixaban | 71 | $67,989 |
| MounjaroTirzepatide | 55 | $66,912 |
| JanuviaSitagliptin Phosphate | 31 | $51,665 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 32 | $33,752 |
| RybelsusSemaglutide | 19 | $27,066 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $22,554 |
| FarxigaDapagliflozin Propanediol | 12 | $19,992 |
| MyrbetriqMirabegron | 19 | $18,922 |
| TrulicityDulaglutide | 15 | $16,011 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $14,081 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $13,772 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $10,129 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,738 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $770 | $173,895136 claims |
| Boehringer IngelheimJardiance | $213 | $115,01490 claims |
| MerckJanuvia, Janumet Xr | $18 | $85,41763 claims |
| Lilly USA, LLCMounjaro, Trulicity | $100 | $82,92470 claims |
| PfizerEliquis, Paxlovid | $52 | $69,41991 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $138 | $36,63558 claims |
| AstraZenecaFarxiga, Symbicort | $219 | $25,73028 claims |
| Astellas Pharma US IncMyrbetriq | $161 | $18,92219 claims |
| AbbVieSynthroid | $88 | $3,32047 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Bloomfield
- Bechara BarrakBloomfield$30K
- John WenceslaoBloomfield$30K
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.